Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Director Sells $56,250.00 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Director Alec Machiels sold 1,250 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $45.00, for a total transaction of $56,250.00. Following the sale, the director now owns 367,420 shares in the company, valued at $16,533,900. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Alec Machiels also recently made the following trade(s):

• On Friday, September 15th, Alec Machiels sold 1,250 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $45.34, for a total value of $56,675.00.
• On Monday, July 17th, Alec Machiels sold 1,250 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $64.79, for a total value of $80,987.50.

Apellis Pharmaceuticals Stock Performance

NASDAQ:APLS traded up $1.30 during mid-day trading on Tuesday, hitting $48.30. The stock had a trading volume of 7,118,655 shares, compared to its average volume of 2,789,152. The company has a 50 day simple moving average of $39.66 and a 200-day simple moving average of $66.62. The company has a current ratio of 5.11, a quick ratio of 4.52 and a debt-to-equity ratio of 0.27. The stock has a market capitalization of $5.69 billion, a price-to-earnings ratio of -8.48 and a beta of 1.08. Apellis Pharmaceuticals, Inc. has a 52 week low of $19.83 and a 52 week high of $94.75.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Monday, July 31st. The company reported ($1.02) EPS for the quarter, beating the consensus estimate of ($1.35) by $0.33. The business had revenue of $95.00 million for the quarter, compared to analysts’ expectations of $70.38 million. Apellis Pharmaceuticals had a negative net margin of 356.02% and a negative return on equity of 212.82%. Apellis Pharmaceuticals’s revenue was up 482.8% on a year-over-year basis. During the same period in the previous year, the company posted ($1.46) EPS. On average, research analysts expect that Apellis Pharmaceuticals, Inc. will post -4.89 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Avoro Capital Advisors LLC boosted its stake in shares of Apellis Pharmaceuticals by 4.6% in the 1st quarter. Avoro Capital Advisors LLC now owns 11,111,111 shares of the company’s stock valued at $732,889,000 after purchasing an additional 486,111 shares during the last quarter. Vanguard Group Inc. raised its holdings in Apellis Pharmaceuticals by 3.5% in the third quarter. Vanguard Group Inc. now owns 9,031,079 shares of the company’s stock worth $616,823,000 after purchasing an additional 304,334 shares during the period. BlackRock Inc. raised its stake in Apellis Pharmaceuticals by 1.0% during the 1st quarter. BlackRock Inc. now owns 5,923,920 shares of the company’s stock worth $300,993,000 after buying an additional 58,208 shares during the period. T. Rowe Price Investment Management Inc. lifted its holdings in Apellis Pharmaceuticals by 5.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 5,842,660 shares of the company’s stock worth $302,124,000 after acquiring an additional 326,537 shares in the last quarter. Finally, EcoR1 Capital LLC grew its stake in Apellis Pharmaceuticals by 5.2% in the first quarter. EcoR1 Capital LLC now owns 5,451,647 shares of the company’s stock valued at $359,591,000 after acquiring an additional 268,216 shares during the period. 90.43% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have commented on APLS. Robert W. Baird lowered their price objective on shares of Apellis Pharmaceuticals from $115.00 to $70.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 1st. Raymond James reduced their price objective on Apellis Pharmaceuticals from $156.00 to $89.00 and set a “strong-buy” rating for the company in a report on Tuesday, August 1st. Bank of America boosted their target price on Apellis Pharmaceuticals from $40.00 to $43.00 and gave the company a “neutral” rating in a research note on Friday, September 8th. Needham & Company LLC reiterated a “buy” rating and set a $60.00 price target on shares of Apellis Pharmaceuticals in a research note on Wednesday, August 30th. Finally, Wells Fargo & Company raised shares of Apellis Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $34.00 to $64.00 in a research report on Friday. Five equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $66.13.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA).